Health Care • Biotechnology: Pharmaceutical Preparations
$14.52 ▼ -0.07
(-0.48%)
MKT CAP: $896.9M • VOL: 248.2K
52W L $12 52W H $50
OBX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 |
|---|---|---|
| Revenue (Total Sales) | $0 | $0 |
| YoY Revenue Growth % | — | — |
| Gross Profit | — | — |
| Gross Margin % | — | — |
| Research & Development (R&D) | — | — |
| Operating Income (EBIT) | -$105.7M | -$91.3M |
| Operating Margin % | — | — |
| Net Income (GAAP) | -$100.6M | -$83.1M |
| EBITDA (Normalized) | -$105.6M | -$90.6M |
| Diluted EPS ($/sh) | — | — |
| Operating Cash Flow (OCF) | -$90.4M | -$75.0M |
| Capital Expenditures (CapEx) | $73.0K | $779.0K |
| Free Cash Flow (FCF) | -$90.5M | -$75.8M |
| FCF Margin % | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% |
| Cash & Short-Term Equivalents | $40.4M | $49.8M |
| Total Debt (Short + Long Term) | — | — |
| Total Stockholders' Equity | -$266.0M | -$174.4M |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR OBX.